<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34694425</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>269</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Influence of a clinical trial in the decision-making processes of patients with amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>2634</StartPage><EndPage>2640</EndPage><MedlinePgn>2634-2640</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-021-10862-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Amyotrophic lateral sclerosis (ALS) is an incurable neurological disease, and patients diagnosed with ALS have a survival time of 2-5&#xa0;years without life-sustaining therapy. Decision-making processes for the acceptance or decline of percutaneous endoscopic gastrostomy (PEG) and tracheostomy with invasive ventilation (TIV) therapy are complex and multifaceted. In this study, we examined whether participation or no participation in clinical trials of ALS had an influence on the decision-making processes of ALS patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Fifty-seven consecutive ALS participants were recruited. Two participants did not wish to participate in any clinical trials, and Twenty-two participants were enrolled in clinical trials. Twenty-three participants wished to participate but could not be enrolled in any of the clinical trials because they exceeded the number of participants in these trials or they met the exclusion criteria.</AbstractText><AbstractText Label="RESULT" NlmCategory="RESULTS">At baseline, there was no significant difference in the preference rates for PEG and TIV between the participant and non-participant groups, but after the double-blind period/6&#xa0;months, both preference rates were significantly higher in the non-participant group than in the participant group. Notably, the rate of preferred TIV in the participant group drastically decreased after the double-blind period. A single regression analysis revealed that participation in clinical trials had a strong influence on the change of TIV preference for 6&#xa0;months.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Participation in a clinical trial decreases the willingness to prolong life after the clinical trial. The present results are meaningful when designing clinical trials and discussing life-sustaining treatments with ALS patients.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morimoto</LastName><ForeName>Satoru</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology, Keio University School of Medicine, Tokyo, 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Shinichi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology, Keio University School of Medicine, Tokyo, 160-8582, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Stroke, Saitama Medical University International Medical Center, Saitama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dat&#xe9;</LastName><ForeName>Yugaku</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okada</LastName><ForeName>Kensuke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okano</LastName><ForeName>Hideyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Physiology, Keio University School of Medicine, Tokyo, 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakahara</LastName><ForeName>Jin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-4740-1675</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. d-ito@jk9.so-net.ne.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>21H02812</GrantID><Agency>Ministry of Education, Culture, Sports, Science and Technology of Japan</Agency><Country/></Grant><Grant><GrantID>JP 18ek0109395</GrantID><Agency>Japan Agency for Medical Research and Development</Agency><Country/></Grant><Grant><GrantID>JP 19ek0109395</GrantID><Agency>Japan Agency for Medical Research and Development</Agency><Country/></Grant><Grant><GrantID>JP 20ek0109395</GrantID><Agency>Japan Agency for Medical Research and Development</Agency><Country/></Grant><Grant><GrantID>JP 18ek0109329</GrantID><Agency>Japan Agency for Medical Research and Development</Agency><Country/></Grant><Grant><GrantID>JP 19ek0109329</GrantID><Agency>Japan Agency for Medical Research and Development</Agency><Country/></Grant><Grant><GrantID>JP 20ek0109329</GrantID><Agency>Japan Agency for Medical Research and Development</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="Y">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003657" MajorTopicYN="Y">Decision Making</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014139" MajorTopicYN="N">Tracheostomy</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Clinical trial</Keyword><Keyword MajorTopicYN="N">Decision-making</Keyword><Keyword MajorTopicYN="N">Percutaneous endoscopic gastrostomy with invasive ventilation</Keyword><Keyword MajorTopicYN="N">Tracheostomy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>25</Day><Hour>12</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34694425</ArticleId><ArticleId IdType="doi">10.1007/s00415-021-10862-6</ArticleId><ArticleId IdType="pii">10.1007/s00415-021-10862-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Charcot JM (1880) De la scl&#xe9;rose lat&#xe9;rale amyotrophique - Symptomatologie Le&#xe7;ons sur les maladies du syst&#xe8;me nerveux, faites &#xe0; la Salp&#xea;tri&#xe8;re. Delahaye, Paris</Citation></Reference><Reference><Citation>Charcot JM (1887&#x2013;1888) Les Le&#xe7;ons du Mardi: Policlinique. Paris: Bureaux du Progr&#xe8;s M&#xe9;dical.</Citation></Reference><Reference><Citation>Goetz CG (2000) Amyotrophic lateral sclerosis: early contributions of Jean-Martin Charcot. Muscle Nerve 23:336&#x2013;343</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4598(200003)23:3&lt;336::AID-MUS4&gt;3.0.CO;2-L</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal MK (2019) Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs. Med Res Rev 39:733&#x2013;748</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21528</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD (2017) Edaravone: a new drug approved for ALS. Cell 171:725</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.10.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al-Chalabi A (2017) Amyotrophic lateral sclerosis. N Engl J Med 377:162&#x2013;172</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi N, Atsuta N, Yokoi D, Nakamura R, Nakatochi M, Katsuno M, Izumi Y, Kanai K, Hattori N, Taniguchi A, Morita M, Kano O, Shibuya K, Kuwabara S, Suzuki N, Aoki M, Aiba I, Mizoguchi K, Oda M, Kaji R, Sobue G (2020) Prognosis of amyotrophic lateral sclerosis patients undergoing tracheostomy invasive ventilation therapy in Japan. J Neurol Neurosurg Psychiatry 91:285&#x2013;290</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-322213</ArticleId></ArticleIdList></Reference><Reference><Citation>Neudert C, Oliver D, Wasner M, Borasio GD (2001) The course of the terminal phase in patients with amyotrophic lateral sclerosis. J Neurol 248:612&#x2013;616</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004150170140</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PM, Kuzma-Kozakiewicz M, Keller J, Aho-Oezhan HEA, Ciecwierska K, Szejko N, Vazquez C, Bohm S, Badura-Lotter G, Meyer T, Petri S, Linse K, Hermann A, Semb O, Stenberg E, Nackberg S, Dorst J, Uttner I, Haggstrom AC, Ludolph AC, Lule D (2018) Therapeutic decisions in ALS patients: cross-cultural differences and clinical implications. J Neurol 265:1600&#x2013;1606</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-8861-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritsma BR, Berger MJ, Charland DA, Khoury MA, Phillips JT, Quon MJ, Strong MJ, Schulz VM (2010) NIPPV: prevalence, approach and barriers to use at Canadian ALS centres. Can J Neurol Sci 37:54&#x2013;60</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0317167100009653</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechtzin N, Wiener CM, Clawson L, Davidson MC, Anderson F, Gowda N, Diette GB, Group ACS (2004) Use of noninvasive ventilation in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 5:9&#x2013;15</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820310017335</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Calvo A, Ghiglione P, Mazzini L, Mutani R, Mora G, Parals (2010) Tracheostomy in amyotrophic lateral sclerosis: a 10-year population-based study in Italy. J Neurol Neurosurg Psychiatry 81:1141&#x2013;1143</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.175984</ArticleId></ArticleIdList></Reference><Reference><Citation>Tagami M, Kimura F, Nakajima H, Ishida S, Fujiwara S, Doi Y, Hosokawa T, Yamane K, Unoda K, Hirose T, Tani H, Ota S, Ito T, Sugino M, Shinoda K, Hanafusa T (2014) Tracheostomy and invasive ventilation in Japanese ALS patients: decision-making and survival analysis: 1990&#x2013;2010. J Neurol Sci 344:158&#x2013;164</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2014.06.047</ArticleId></ArticleIdList></Reference><Reference><Citation>Vianello A, Concas A (2014) Tracheostomy ventilation in ALS: a Japanese bias. J Neurol Sci 344:3&#x2013;4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2014.06.050</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurisaki R, Yamashita S, Sakamoto T, Maruyoshi N, Uekawa K, Uchino M, Ando Y (2014) Decision making of amyotrophic lateral sclerosis patients on noninvasive ventilation to receive tracheostomy positive pressure ventilation. Clin Neurol Neurosurg 125:28&#x2013;31</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clineuro.2014.07.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabkin J, Ogino M, Goetz R, McElhiney M, Hupf J, Heitzman D, Heiman-Patterson T, Miller R, Katz J, Lomen-Hoerth C, Imai T, Atsuta N, Morita M, Tateishi T, Matsumura T, Mitsumoto H (2014) Japanese and American ALS patient preferences regarding TIV (tracheostomy with invasive ventilation): a cross-national survey. Amyotroph Lateral Scler Frontotemporal Degener 15:185&#x2013;191</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.896928</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenaway LP, Martin NH, Lawrence V, Janssen A, Al-Chalabi A, Leigh PN, Goldstein LH (2015) Accepting or declining non-invasive ventilation or gastrostomy in amyotrophic lateral sclerosis: patients&#x2019; perspectives. J Neurol 262:1002&#x2013;1013</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-015-7665-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Christodoulou G, Goetz R, Ogino M, Mitsumoto H, Rabkin J (2015) Opinions of Japanese and American ALS caregivers regarding tracheostomy with invasive ventilation (TIV). Amyotroph Lateral Scler Frontotemporal Degener 17:47&#x2013;54</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1069850</ArticleId></ArticleIdList></Reference><Reference><Citation>Morimoto S, Takahashi S, Fukushima K, Saya H, Suzuki N, Aoki M, Okano H, Nakahara J (2019) Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis - Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial). Regen Ther 11:143&#x2013;166</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.reth.2019.07.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi S (2020) Phase 1/2a, Double-blind, Placebo-controlled Study with an Open-label Extension of Ropinirole Hydrochloride Extended-Release Tablets-Explorative Assessment of the Safety, Tolerability, and Efficacy after Oral Treatment in Patients with Amyotrophic Lateral Sclerosis (ALS) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000039856 . Accessed 21 Nov 2021</Citation></Reference><Reference><Citation>Okano H, Yasuda D, Fujimori K, Morimoto S, Takahashi S (2020) Ropinirole, a new ALS drug candidate developed using iPSCs. Trends Pharmacol Sci 41:99&#x2013;109</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2019.12.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Biogen (2021) An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS) (VALOR (Part C)) https://clinicaltrials.gov/ct2/show/NCT02623699 . Accessed 24 Mar 2021</Citation></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron D (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1:293&#x2013;299</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId></ArticleIdList></Reference><Reference><Citation>Team RC (2021) A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>